Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Candel Therapeutics, Inc. CADL
$1.55
-$0.12 (-7.74%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
49408740.00000000
-
week52high
4.25
-
week52low
1.15
-
Revenue
125000
-
P/E TTM
5
-
Beta
0.00000000
-
EPS
-0.79000000
-
Last Dividend
0.00000000
-
Next Earnings Date
11 мая 2023 г. в 04:00
Описание компании
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| BMO Capital | Outperform | Outperform | 31 мар 2022 г. |
| BMO Capital | Outperform | 19 ноя 2021 г. | |
| UBS | Buy | 23 авг 2021 г. | |
| Jefferies | Buy | 23 авг 2021 г. | |
| Credit Suisse | Outperform | 23 авг 2021 г. | |
| BMO Capital | Outperform | Outperform | 02 сент 2022 г. |
| Credit Suisse | Outperform | Outperform | 07 дек 2022 г. |
| HC Wainwright & Co. | Buy | 02 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Tak Paul Peter | A | 40985 | 12935 | 09 дек 2022 г. |
| Amello Jason | A | 5568 | 2468 | 09 дек 2022 г. |
| Tyagarajan Seshu | A | 13358 | 10358 | 09 дек 2022 г. |
| Martell Christopher | A | 152000 | 23950 | 09 дек 2022 г. |
| PAPA JOSEPH C | A | 38032 | 35018 | 09 дек 2022 г. |
| Barone Francesca | A | 2738 | 1238 | 08 дек 2022 г. |
| Tak Paul Peter | A | 28050 | 3050 | 08 дек 2022 г. |
| Amello Jason | A | 3100 | 3100 | 08 дек 2022 г. |
| Tyagarajan Seshu | A | 3000 | 3000 | 08 дек 2022 г. |
| Martell Christopher | A | 128050 | 3050 | 08 дек 2022 г. |
Новостная лента
Candel Therapeutics Upcoming Investor Conference Participation for November
GlobeNewsWire
01 ноя 2022 г. в 08:00
NEEDHAM, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will participate in the following investor conferences in November:
Candel Therapeutics Upcoming Investor Conference Participation
GlobeNewsWire
06 сент 2022 г. в 08:00
NEEDHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer will participate in two upcoming investor conferences.